Biodesix Inc. (BDSX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?
The mean of analysts' price targets for Biodesix (BDSX) points to a 103.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to a loss of $1.6 per share a year ago.
Wall Street Analysts See an 86.45% Upside in Biodesix (BDSX): Can the Stock Really Move This High?
The mean of analysts' price targets for Biodesix (BDSX) points to an 86.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?
Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet
The mean of analysts' price targets for Biodesix (BDSX) points to an 111.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript
Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript
Biodesix, Inc. (BDSX) Reports Q4 Loss, Beats Revenue Estimates
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $1.2 per share a year ago.
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 325.67%: Here's is How to Trade
The mean of analysts' price targets for Biodesix (BDSX) points to a 325.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates
Biodesix, Inc. (BDSX) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.6. This compares to a loss of $1.4 per share a year ago.
Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript
Biodesix, Inc. ( BDSX ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Scott Hutton - President, CEO & Director Robin Cowie - CFO, Secretary & Treasurer Conference Call Participants Christopher Brinzey - Westwicke Partners, LLC Margarate Boeye - William Blair & Company L.L.C., Research Division Alexander Vukasin - Canaccord Genuity Corp., Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division William Ruby - TD Cowen, Research Division Presentation Operator " Christopher Brinzey Westwicke Partners, LLC " Scott Hutton President, CEO & Director " Robin Cowie CFO, Secretary & Treasurer " Margarate Boeye William Blair & Company L.L.C.
